Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort

Cancer Research

Volumn 71, Issue 5, 2011, Pages 1763-1771

  Jacobs, Eric J ^a   Newton, Christina C ^a   Thun, Michael J ^a   Gapstur, Susan M ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RISK; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DRUG USE; ENDOMETRIUM CANCER; FEMALE; HUMAN; KIDNEY CANCER; LONG TERM CARE; LUNG CANCER; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PLASMACYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION; UNITED STATES;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; UNITED STATES;

EID: 79952233121     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2953     Document Type: Article

References (57)

1. Lemaitre RN, Furberg CD, Newman AB, Hulley SB, Gordon DJ, Gottdiener JS, et al. Time trends in the use of cholesterol-lowering agents in older dults: The Cardiovascular Health Study. Arch Intern Med 1998;158:1761-8. (Pubitemid 28421419)
2. Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 2000;108:496-9.
3. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008;42:1208-15.
4. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769-81.
5. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Can 2005;5:930-42. (Pubitemid 41766782)
6. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4:977-87.
7. Zeiser R, Maas K, Youssef S, Durr C, Steinman L, Negrin RS. Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology 2009;127:18-25.
8. Chan KY, Boucher ES, Gandhi PJ, Silva MA. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health-Syst Pharm 2004;61:1676-81. (Pubitemid 39481377)
9. Browning DR, Martin RM. Statins and risk of cancer: A systematic review and metaanalysis. Int J Cancer 2007;120:833-43. (Pubitemid 46175404)
10. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf.
11. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr., Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;1727-36.
12. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort - rationale, study design and baseline characteristics. Cancer 2002;94:2490-501. (Pubitemid 34457132)
13. Bergmann MM, Calle EE, Mervis CA, Miracle-McMahill JL, Thun MJ, Heath CW. Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries. Am J Epidemiol 1998;147:556-62. (Pubitemid 28134242)
14. Calle EE, Terrell DD. Utility of the national death index for ascertainment of mortality among Cancer Prevention Study II participants. Am J Epidemiol 1993;137:235-41. (Pubitemid 23083676)
15. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (B) 1972;34:187-220.
16. Kleinbaum DG. Survival Analysis: a Self-Learning Text. New York: Springer-Verlag;1996.
17. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110: 695-708. (Pubitemid 47105409)
18. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007; 16:2213-7. (Pubitemid 351196351)
19. American Joint Committee on Cancer. AJCC Cancer Staging Manual. Sixth ed. New York: Springer;2002.
20. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr., Habel LA. Erratum: Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf 2008; 17:751.
21. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-Hydroxyl-3Methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women. Cancer 2004;100:2308-16. (Pubitemid 38657877)
22. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005;165:2264-71. (Pubitemid 41549923)
23. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16:416-21. (Pubitemid 46548643)
24. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-9.
25. Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98: 1819-25. (Pubitemid 46017933)
26. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007;16: 2218-25. (Pubitemid 351196352)
27. Murtola TJ, Tammela TL, Maattanen L, Huhtala H, Platz EA, Ala- Opas M, et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer 2010;127: 1650-9.
28. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008;168:250-60. (Pubitemid 352019786)
29. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92. (Pubitemid 40727085)
30. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006;98:69-72. (Pubitemid 43057094)
31. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007;99:32-40.
32. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007;133:393-402. (Pubitemid 47187349)
33. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007;131:1282-8. (Pubitemid 46762329)
34. Khurana V, Sheth A, Caldito G, Barkin JS. Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 2007;34:260-5. (Pubitemid 46294804)
35. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested casecontrol study. Arch Intern Med 2000;160:2363-8.
36. Yu O, Boudreau DM, Buist DS, Miglioretti DL. Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes Control 2009;20:609-16.
37. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, et al. Incidence of cancer and statin usage-record linkage study. Int J Cancer 2010;126:279-84.
38. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008;100:134-9. (Pubitemid 351480564)
39. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
40. Holly EA, Lele C, Bracci PM, McGrath MS. Case-control study of non- Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 1999;150:375-89. (Pubitemid 29383486)
41. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419-28. (Pubitemid 38988028)
42. Fortuny J, de Sanjose S, Becker N, Maynadié M, Cocco PL, Staines A, et al. Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH. Cancer Epidemiol Biomarkers Prev 2006;5:921-5. (Pubitemid 43823519)
43. Iwata H, Matsuo K, Hara S, Takeuchi K, Aoyama T, Murashige N, et al. Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci 2006;97: 133-8. (Pubitemid 43379481)
44. Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer 2009;124:1497-502.
45. Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, Warren JL, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009;125:398-405.
46. Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 2008;112:5150-60.
47. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107:904-6. (Pubitemid 43156286)
48. Sherwin RW, Wentworth DN, Cutler JA, Hulley SB, Kuller LH, Stamler J. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. Jama 1987; 257:943-8. (Pubitemid 17024387)
49. Ajith TA, Harikumar KB, Thasna H, Sabu MC, Babitha NV. Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice. Clin Chim Acta 2006;366:322-8. (Pubitemid 43331003)
50. Shachaf CM, Perez OD, Youssef S, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 2007;110:2674-84. (Pubitemid 47523192)
51. Clendening JW, Pandyra A, Li Z, Boutros PC, Martirosyan A, Lehner R, et al. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood 2010;115:4787-97.
52. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15: 2069-77. (Pubitemid 44877028)
53. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44. (Pubitemid 41640845)
54. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796-803. (Pubitemid 43799181)
55. Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029-38.
56. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 2007;139:730-43. (Pubitemid 350115735)
57. Thompson MA, Kyle RA, Melton LJ, Plevak MF, Rajkumar SV. Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study. Haematologica 2004;89:626-8. (Pubitemid 38691260)